---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-053500"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2023-06-30T23:59:59+00:00"
generated_at: "2026-06-13T14:22:10.736837+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Allarity enters $350K secured note with 3i LP; amends preferred conversion price to $8.00

## Summary
- Issued $350,000 secured promissory note to 3i LP, maturing July 31, 2023, at 5% annual interest.
- Note secured by all company assets; proceeds for working capital and general corporate purposes.
- Filed Second Certificate of Amendment reducing Series A Preferred conversion price from $0.75 to $8.00, reflecting 1:40 reverse stock split.
- Outstanding obligations payable at next financing or convertible into 486 Series A Preferred shares if insufficient proceeds.
- 3i LP is the sole holder of Series A Preferred and has existing relationship with the company.

## SEC filing metadata
- accession: 0001213900-23-053500
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2023-06-30T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/0001213900-23-053500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/ea181165-8k_allarity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-053500
- JSON: https://secwatch.observer/filing/0001213900-23-053500.json
- Plain text: https://secwatch.observer/filing/0001213900-23-053500.txt

## Key facts
- Debt Financings
  Allarity Therapeutics, Inc. incurred loan of $350,000 with 3i LP at 5% per annum maturing July 31, 2023.
  - Instrument: loan
  - Principal: $350,000
  - Counterparty: 3i LP
  - Rate: 5% per annum
  - Maturity: July 31, 2023
  - Event: incurrence
  source text: Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000 to be issued at closing (the “Note”). The closing for the Note occurred on June 30, 2023 and the purchase price for the Note was paid in cash (“Closing”). The Note matures on July 31, 2023, carries an interest rate of at 5% per annum
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/0001213900-23-053500-index.htm
- Material Agreements
  Allarity Therapeutics, Inc. entered into Secured Note Purchase Agreement with 3i LP valued at $350,000 (effective 2023-06-29).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: 3i LP
  - Value: $350,000
  - Effective: 2023-06-29
  source text: On June 29, 2023, Allarity Therapeutics, Inc. (the “Company”) entered into a Secured Note Purchase Agreement (“Purchase Agreement”) with 3i LP, the sole holder of the Company’s outstanding shares of Series A Preferred Stock. Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/0001213900-23-053500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.